A5065282629- Venous Thromboembolism Diagnosis and Management
- Atrial Fibrillation Management and Outcomes
- Acute Ischemic Stroke Management
- Cardiac, Anesthesia and Surgical Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Antiplatelet Therapy and Cardiovascular Diseases
- Peripheral Artery Disease Management
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Cardiac Arrhythmias and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac electrophysiology and arrhythmias
- Clinical practice guidelines implementation
- Cardiac pacing and defibrillation studies
- Lipoproteins and Cardiovascular Health
- Cerebrovascular and Carotid Artery Diseases
- Intramuscular injections and effects
- Meta-analysis and systematic reviews
- Diabetes Treatment and Management
- Pharmaceutical Economics and Policy
- Blood Pressure and Hypertension Studies
- Total Knee Arthroplasty Outcomes
- Central Venous Catheters and Hemodialysis
- Hip and Femur Fractures
University of Connecticut
2016-2025
Hartford Hospital
2016-2025
Hartford Financial Services (United States)
2014-2025
Janssen (United States)
2016-2023
Janssen Scientific Affairs (United States)
2016-2023
University of Cincinnati
2023
University of Michigan–Ann Arbor
2023
Aalborg University Hospital
2023
Coleman University
2015-2022
Evidence Based Research (United States)
2010-2020
Angiotensin II has been shown to increase hepatic glucose production and decrease insulin sensitivity. Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes.Three reviewers conducted systematic literature search Medline, EMBASE, CINAHL, the Cochrane Library (1966 present) extract consensus trial data involving ACEI ARB with end point diabetes. Studies were included if they randomized...
Rivaroxaban was shown to be effective in reducing the risk of stroke and systemic embolism patients with nonvalvular atrial fibrillation (AF) a randomized controlled trial setting.To assess real-world safety, effectiveness, persistence associated rivaroxaban warfarin AF patients.Healthcare claims from Symphony Health Solutions' Patient Transactional Datasets May 2011 July 2012 were analyzed. Adult newly initiated on or warfarin, ≥2 diagnoses (ICD-9-CM: 427.31) CHADS2 score ≥1 during 180 day...
Background Frailty predicts poorer outcomes and decreased anticoagulation use in patients with nonvalvular atrial fibrillation. We sought to assess the effectiveness safety of apixaban, dabigatran rivaroxaban versus warfarin frail fibrillation patients. Methods Results Using US MarketScan claims data from November 2011 December 2016, we identified oral anticoagulant‐naïve ≥12 months continuous insurance coverage before anticoagulant initiation. status was determined using Johns Hopkins...
Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent in therapeutic range (TTR), proportion international normalized ratio (INR) measurements (PINRR), adverse events relation INR, and predictors INR control AF using VKAs.We searched MEDLINE, CENTRAL EMBASE (1990-June 2013) for studies receiving adjusted-dose VKAs that reported measures...
Little data exists regarding the effectiveness and safety of rivaroxaban or apixaban versus warfarin in nonvalvular atrial fibrillation (NVAF) patients treated outside clinical trials.This was a retrospective study using MarketScan claims from January 2012 to October 2014. We included adults, newly initiated on rivaroxaban, warfarin, with baseline CHA2DS2-VASc score ≥2, ≥2 diagnosis codes for NVAF ≥180 days continuous medical prescription benefits. Patients prior stroke, systemic embolism...
Limited real-world data exist comparing each non-vitamin K antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial fibrillation who have had a previous ischemic stroke or transient attack.Using MarketScan claims from January 2012 June 2015, we identified adults newly initiated on anticoagulation, ≥2 diagnosis codes for fibrillation, history of stroke/transient attack, and ≥180 days continuous medical prescription benefits before anticoagulation initiation. Three...